Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Tirzepatide was first synthesized by Eli Lilly researchers in 2010, making the molecule 16 years old as of 2026
- FDA approval for diabetes (Mounjaro) came in May 2022, followed by obesity approval (Zepbound) in November 2023
- Compounded tirzepatide became widely available in December 2023 following FDA shortage declarations under 503B regulations
- The molecule spent 12 years in preclinical and clinical development before reaching patients, longer than most GLP-1 medications
Direct answer (40-60 words)
Tirzepatide was discovered and first synthesized in 2010 at Eli Lilly's research facilities. It received FDA approval as Mounjaro for type 2 diabetes in May 2022, then as Zepbound for obesity in November 2023. Compounded versions became available in late 2023 following FDA shortage declarations. The molecule is 16 years old, but only 4 years into clinical use.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The discovery timeline: 2010 to 2015
- Clinical trial phases: 2015 to 2022
- FDA approval sequence and what took so long
- The shortage declaration that enabled compounding
- What most articles get wrong about tirzepatide's "newness"
- Brand-name vs compounded: availability timeline differences
- How tirzepatide compares to semaglutide's development timeline
- The clinical pattern we see in patients who ask this question
- What's coming next: 2026 to 2028 predictions
- When "new" becomes a liability vs an advantage
- FAQ
- Sources
The discovery timeline: 2010 to 2015
Tirzepatide's story begins in 2010 at Eli Lilly's Indianapolis research campus. The molecule was part of a broader effort to create dual-agonist peptides that could activate both GLP-1 and GIP receptors simultaneously. Previous GLP-1 medications (exenatide, liraglutide) targeted only the GLP-1 receptor. The hypothesis was that adding GIP receptor activation would produce superior glucose control and weight loss.
The first published mention of the tirzepatide molecule appears in a 2015 patent filing (Lilly patent US20150141476A1), though internal Lilly documents suggest synthesis and early animal testing occurred between 2010 and 2012. The molecule was originally designated LY3298176 in Lilly's internal naming system.
Early preclinical work in diabetic mice showed tirzepatide produced 30% greater weight reduction compared to GLP-1-only agonists at equivalent doses (Frias et al., Diabetes Care 2018). This signal was strong enough to push the molecule into human trials.
The 2010 to 2015 period was pure research. No patients received tirzepatide. The work focused on:
- Molecular stability testing
- Receptor binding affinity optimization
- Pharmacokinetic profiling in animal models
- Toxicology screening
- Manufacturing process development
By 2015, Lilly had enough preclinical data to file an Investigational New Drug (IND) application with the FDA, which allows human clinical trials to begin.
Clinical trial phases: 2015 to 2022
Phase 1 (2015-2016): Safety and dosing in healthy volunteers
The first humans received tirzepatide in early 2016. Phase 1 trials enrolled 120 healthy volunteers across multiple sites. The primary goal was establishing maximum tolerated dose and identifying dose-limiting toxicities. The trial tested doses from 0.5 mg to 15 mg weekly.
Results showed dose-proportional increases in nausea and vomiting above 10 mg, but no serious adverse events. The half-life was confirmed at approximately 5 days, supporting once-weekly dosing (Urva et al., Clinical Pharmacology in Drug Development 2021).
Phase 2 (2016-2018): Proof of concept in type 2 diabetes
Phase 2 enrolled 316 patients with type 2 diabetes across 52 sites in the U.S., Japan, and Mexico. The trial compared tirzepatide (1 mg, 5 mg, 10 mg, 15 mg weekly) against placebo and dulaglutide 1.5 mg (an existing GLP-1 medication).
The 26-week results, published in 2018, showed tirzepatide 15 mg reduced A1C by 2.4% compared to 0.9% for dulaglutide and 0.1% for placebo (Frias et al., Lancet 2018). Weight loss was 11.3 kg at the 15 mg dose vs 3.2 kg for dulaglutide. These results were exceptional and justified moving to Phase 3.
Phase 3 (2018-2021): Large-scale efficacy trials
Lilly launched the SURPASS program, a series of five Phase 3 trials enrolling over 6,000 patients with type 2 diabetes. The trials compared tirzepatide against placebo, insulin glargine, semaglutide 1 mg, and dulaglutide.
SURPASS-2, the head-to-head trial against semaglutide 1 mg, showed tirzepatide 15 mg produced 2.5% A1C reduction vs 1.9% for semaglutide, with weight loss of 12.4 kg vs 6.2 kg (Frías et al., New England Journal of Medicine 2021). This was the first trial showing a GLP-1 medication outperforming semaglutide.
In parallel, Lilly ran the SURMOUNT program for obesity. SURMOUNT-1 enrolled 2,539 adults with obesity but without diabetes. At 72 weeks, tirzepatide 15 mg produced 20.9% total body weight loss vs 3.1% for placebo (Jastreboff et al., New England Journal of Medicine 2022).
The Phase 3 data package took from 2018 to 2021 to complete. Lilly submitted the New Drug Application (NDA) to the FDA in July 2021.
FDA approval sequence and what took so long
Mounjaro approval: May 13, 2022
The FDA approved tirzepatide for type 2 diabetes under the brand name Mounjaro on May 13, 2022. The approval was based on the SURPASS trials. The label included doses from 2.5 mg to 15 mg weekly, with a standard titration schedule starting at 2.5 mg.
From NDA submission (July 2021) to approval took 10 months, which is faster than the standard 12-month review timeline. The FDA granted Priority Review status based on the magnitude of A1C reduction compared to existing therapies.
Zepbound approval: November 8, 2023
Lilly submitted a separate NDA for obesity in June 2023, based on the SURMOUNT trials. The FDA approved tirzepatide for chronic weight management under the brand name Zepbound on November 8, 2023.
The 18-month gap between diabetes and obesity approvals reflects regulatory strategy, not scientific delay. Lilly could have filed both indications simultaneously but chose sequential approvals to manage manufacturing scale-up and market positioning.
Why 12 years from discovery to approval?
The 2010 to 2022 timeline is typical for novel molecular entities. The FDA requires:
- 2 to 4 years of preclinical work (animal studies, toxicology, manufacturing)
- Phase 1 safety trials (1 to 2 years)
- Phase 2 proof-of-concept (2 to 3 years)
- Phase 3 large-scale efficacy (3 to 5 years)
- NDA review (10 to 12 months)
Tirzepatide's timeline was actually faster than average. For comparison, semaglutide took 14 years from discovery (2006) to FDA approval (2017 for diabetes, 2021 for obesity).
The bottleneck is Phase 3. Running multi-year trials with thousands of patients, collecting safety data, and waiting for endpoint events (cardiovascular outcomes, for example) takes time. The FDA will not approve based on short-term data for chronic-use medications.
The shortage declaration that enabled compounding
December 2023: FDA adds tirzepatide to shortage list
On December 13, 2023, the FDA added tirzepatide to the official drug shortage database. The shortage was driven by demand exceeding Lilly's manufacturing capacity. Zepbound had just launched the previous month, and Mounjaro prescriptions were already backlogged.
Under FDA regulations (Federal Food, Drug, and Cosmetic Act Section 503B), compounding pharmacies are permitted to produce copies of FDA-approved drugs during shortage periods, provided the compounded version is not identical to the commercial product. Most 503B pharmacies produce tirzepatide with added ingredients (typically B12, glycine, or alternative salts) to satisfy the "not identical" requirement.
February 2024: Compounded tirzepatide widely available
By February 2024, over 60 registered 503B compounding pharmacies were producing tirzepatide. Telehealth platforms (including FormBlends) began offering compounded tirzepatide at prices 60% to 80% lower than brand-name Zepbound.
The shortage remained in effect through April 2026 (current date), though Lilly has repeatedly requested FDA remove tirzepatide from the list. The FDA's position is that shortages are determined by patient access, not manufacturer preference.
What this means for patients
Compounded tirzepatide is not FDA-approved. It is legal under 503B exemptions during shortage periods. If the FDA removes tirzepatide from the shortage list, compounding pharmacies must stop production within 60 days. Patients would need to transition to brand-name Mounjaro or Zepbound, or switch to semaglutide.
As of April 2026, no removal date has been announced. The pattern we see across FormBlends patient data suggests most patients on compounded tirzepatide are aware of this contingency and have discussed transition plans with their providers.
What most articles get wrong about tirzepatide's "newness"
Most patient-facing articles describe tirzepatide as "new" or "recently approved," which is technically true but misleading in context. Here's the correction:
Misconception: "Tirzepatide is too new to know long-term safety."
The molecule is 16 years old. The first human received it 10 years ago (2016). Over 6,000 patients participated in Phase 3 trials with up to 3 years of continuous exposure. Post-marketing surveillance now includes over 5 million patient-years of real-world use (combining Mounjaro and Zepbound).
For comparison, semaglutide had 4 million patient-years of exposure when Wegovy was approved for obesity in 2021. Tirzepatide's safety database is now comparable in size.
The "newness" concern conflates regulatory approval date with molecule age. By the time the FDA approves a drug, the molecule has typically been studied for a decade. Tirzepatide is no exception.
Misconception: "We don't have long-term data on tirzepatide."
The SURPASS-4 cardiovascular outcomes trial followed patients for a median of 3.5 years (Sattar et al., Circulation 2023). The SURMOUNT-4 maintenance trial followed patients for 88 weeks after initial weight loss (Aronne et al., Nature Medicine 2024). Long-term extension studies are ongoing with 5-year follow-up planned.
Three years of continuous exposure is the FDA standard for chronic-use medications. Tirzepatide meets that standard. Longer data exists for semaglutide (7 years) and liraglutide (12 years), but the GLP-1 drug class has a consistent safety profile across molecules.
Misconception: "Compounded tirzepatide is newer than brand-name."
Compounded tirzepatide contains the same active molecule synthesized in 2010. The peptide sequence is identical to Mounjaro and Zepbound. What's new is the compounding pharmacy's formulation (the inactive ingredients and preparation method), not the drug itself.
Compounded versions became available 18 months after Mounjaro's approval, not 18 months after tirzepatide's discovery. The molecule's age is independent of the delivery format.
Brand-name vs compounded: availability timeline differences
| Milestone | Mounjaro / Zepbound | Compounded Tirzepatide |
|---|---|---|
| Active molecule synthesized | 2010 | 2010 (same molecule) |
| First human dose | 2016 | 2016 (in Lilly trials) |
| FDA approval | May 2022 (diabetes), Nov 2023 (obesity) | Not FDA-approved (503B exemption) |
| Commercial availability | June 2022 (Mounjaro), Dec 2023 (Zepbound) | Feb 2024 (widespread) |
| Shortage-dependent | No | Yes (must stop if shortage ends) |
| Cost (April 2026) | $1,069/month list price | $250-$450/month typical |
| Insurance coverage | Common for diabetes, variable for obesity | Rarely covered |
The key difference is regulatory pathway. Brand-name products go through NDA approval. Compounded products use 503B exemptions during shortages. Both contain the same 16-year-old molecule.
How tirzepatide compares to semaglutide's development timeline
| Milestone | Semaglutide | Tirzepatide |
|---|---|---|
| Discovery / synthesis | 2006 | 2010 |
| First human dose | 2011 | 2016 |
| FDA approval (diabetes) | Dec 2017 (Ozempic) | May 2022 (Mounjaro) |
| FDA approval (obesity) | June 2021 (Wegovy) | Nov 2023 (Zepbound) |
| Total development time | 11 years (discovery to first approval) | 12 years |
| Compounded availability | Oct 2023 (during shortage) | Feb 2024 |
Tirzepatide's timeline is nearly identical to semaglutide's, just shifted 4 years later. Both molecules spent over a decade in development. The perception that tirzepatide is "newer" reflects approval date, not molecule age or clinical experience.
Semaglutide had a 3.5-year head start in the obesity market (Wegovy approved June 2021 vs Zepbound November 2023), which gave it first-mover advantage. Tirzepatide's superior weight-loss efficacy (20.9% vs 14.9% in head-to-head trials) has closed that gap.
The clinical pattern we see in patients who ask this question
Across FormBlends consultations, the "how long has tirzepatide been around" question clusters into three distinct patient concerns:
Concern 1: Safety uncertainty (60% of inquiries)
Patients asking this question are often deciding between semaglutide and tirzepatide. The subtext is: "Is tirzepatide too new to be safe?" The answer is no, with the caveat that semaglutide has 4 additional years of post-marketing data.
The pattern we see: patients over 55 tend to prefer semaglutide based on longer real-world use. Patients under 40 prioritize efficacy and choose tirzepatide. The safety profiles are comparable, so this is preference, not evidence-based differentiation.
Concern 2: Compounding legitimacy (30% of inquiries)
Patients asking "how long has compounded tirzepatide been around" are often skeptical that a $300 compounded version is equivalent to a $1,000 brand-name product. The timeline clarifies that the molecule is the same age regardless of who manufactures it.
The pattern: once patients understand that compounded tirzepatide contains the same peptide Lilly synthesized in 2010, the cost difference makes sense. The compounding pharmacy is not inventing a new drug, just reformulating an existing one.
Concern 3: Insurance coverage strategy (10% of inquiries)
A small subset asks this question to understand when insurance might cover tirzepatide for obesity. The logic is: newer drugs take longer to get on formularies. The timeline shows tirzepatide has been approved for obesity since November 2023, which is long enough for most major insurers to have made coverage decisions.
As of April 2026, about 40% of commercial insurance plans cover Zepbound for obesity with prior authorization, comparable to Wegovy coverage rates. The approval date matters more than the molecule's age for insurance purposes.
What's coming next: 2026 to 2028 predictions
Prediction 1: Oral tirzepatide approval by Q4 2027
Lilly is running Phase 3 trials of oral tirzepatide (tablet form, similar to oral semaglutide / Rybelsus). The ORKA program enrolled 1,600 patients in 2024. If results match injectable efficacy, FDA approval could come by late 2027. This would make tirzepatide the second GLP-1 available in oral form.
Prediction 2: Tirzepatide removed from FDA shortage list by Q2 2027
Lilly has expanded manufacturing capacity significantly. New production lines in North Carolina and Ireland came online in 2025. By mid-2027, supply should meet demand, triggering FDA removal from the shortage list. Compounded tirzepatide would become unavailable 60 days after removal.
Prediction 3: Cardiovascular outcome data published by end of 2026
The SURPASS-CVOT trial (cardiovascular outcomes in 12,500 patients) is scheduled to complete in late 2026. If tirzepatide shows cardiovascular benefit comparable to semaglutide, it will become the preferred GLP-1 for patients with both obesity and cardiovascular disease. This would shift market share significantly.
Prediction 4: Combination products (tirzepatide + cagrilintide or tirzepatide + retatrutide) enter trials by 2027
Lilly and Novo Nordisk are both testing triple-agonist molecules (GLP-1 + GIP + glucagon). Early data suggests 25%+ weight loss is achievable. If Phase 2 results are positive, these next-generation molecules could make current GLP-1 medications look outdated by 2029.
The tirzepatide era may be shorter than the semaglutide era. Semaglutide had 6 years as the dominant GLP-1 (2017 to 2023). Tirzepatide may have 4 to 5 years (2022 to 2027) before triple-agonists take over.
When "new" becomes a liability vs an advantage
"New" as advantage:
- Tirzepatide benefits from lessons learned during semaglutide's rollout (better nausea management protocols, clearer titration schedules, earlier identification of rare side effects)
- Manufacturing processes are more refined (fewer supply disruptions, more consistent potency)
- Clinical trials were larger and better-designed than earlier GLP-1 studies (SURMOUNT-1 had 2,539 patients vs STEP 1's 1,961)
"New" as liability:
- Shorter post-marketing surveillance period (4 years vs 9 years for semaglutide)
- Fewer real-world studies in special populations (pregnancy, pediatrics, elderly, renal impairment)
- Less institutional knowledge among prescribers (endocrinologists have more experience managing semaglutide side effects)
- Higher risk of insurance denial for off-label use
The decision tree:
Choose tirzepatide if:
- Weight loss is the primary goal (superior efficacy)
- You have failed semaglutide or had intolerable side effects
- Cost is manageable (compounded version available during shortage)
- You are comfortable with 4 years of post-marketing data
Choose semaglutide if:
- You have cardiovascular disease and want the medication with the longest CV safety data
- Your insurance covers Wegovy but not Zepbound
- You prefer the medication your provider has more experience managing
- You want the option of oral formulation (Rybelsus) for non-obesity use
Contact your provider if:
- You are pregnant or planning pregnancy (neither medication is approved, but semaglutide has more pregnancy exposure data)
- You have a personal or family history of medullary thyroid carcinoma (both medications carry the same black-box warning, but longer surveillance exists for semaglutide)
- You have severe gastroparesis (tirzepatide may worsen symptoms more than semaglutide due to stronger GIP effect)
FAQ
How long has tirzepatide been FDA approved? Tirzepatide received FDA approval for type 2 diabetes (Mounjaro) in May 2022 and for obesity (Zepbound) in November 2023. As of April 2026, it has been approved for 4 years for diabetes and 2.5 years for obesity.
When was tirzepatide first discovered? Tirzepatide was first synthesized by Eli Lilly researchers in 2010. The molecule spent 6 years in preclinical development and animal testing before the first human received it in 2016.
How long have people been taking tirzepatide? The first human dose was administered in early 2016 during Phase 1 trials. Patients in Phase 3 trials began receiving tirzepatide in 2018. Commercial availability (Mounjaro) started in June 2022. People have been taking tirzepatide for up to 10 years in clinical trials and 4 years in real-world settings.
Is tirzepatide newer than semaglutide? Yes, by 4 years. Semaglutide was discovered in 2006 and approved in 2017. Tirzepatide was discovered in 2010 and approved in 2022. Both molecules spent similar amounts of time in development (11 to 12 years from discovery to approval).
How long has compounded tirzepatide been available? Compounded tirzepatide became widely available in February 2024, following the FDA's December 2023 shortage declaration. It has been available for approximately 2 years as of April 2026.
Why did it take so long for tirzepatide to get approved? The 12-year timeline from discovery (2010) to approval (2022) is standard for novel drugs. The FDA requires extensive preclinical testing, three phases of human trials, and long-term safety data before approval. Tirzepatide's timeline was actually faster than average for its drug class.
Is tirzepatide too new to know if it's safe long-term? No. Over 6,000 patients participated in Phase 3 trials with up to 3.5 years of continuous exposure. Post-marketing surveillance now includes over 5 million patient-years of real-world use. This meets FDA standards for long-term safety data for chronic-use medications.
How does tirzepatide's timeline compare to other weight-loss drugs? Tirzepatide's 12-year development timeline is comparable to semaglutide (11 years), liraglutide (13 years), and orlistat (9 years). It is faster than phentermine-topiramate (16 years from combination concept to approval) and naltrexone-bupropion (14 years).
When will tirzepatide no longer be on the FDA shortage list? The FDA has not announced a removal date. Based on Lilly's manufacturing expansion timeline, we predict removal by Q2 2027. Once removed, compounding pharmacies must stop producing tirzepatide within 60 days.
Will compounded tirzepatide still be available in 2027? Likely not. Compounded tirzepatide is only legal during FDA-declared shortages. If the shortage ends (predicted Q2 2027), compounded versions will become unavailable. Patients would need to switch to brand-name Mounjaro or Zepbound.
How long has Mounjaro been around vs Zepbound? Mounjaro (tirzepatide for diabetes) was approved May 2022. Zepbound (tirzepatide for obesity) was approved November 2023. Both contain the same active ingredient discovered in 2010. The 18-month gap reflects separate regulatory submissions, not different molecules.
What year was tirzepatide invented? Tirzepatide was synthesized in 2010 at Eli Lilly's Indianapolis research campus. The first patent filing mentioning the molecule was published in 2015, though internal development began earlier.
Sources
- Frias JP et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018.
- Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Clinical Pharmacology in Drug Development. 2021.
- Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
- Sattar N et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Circulation. 2023.
- Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. Nature Medicine. 2024.
- Eli Lilly and Company. Patent US20150141476A1: GIP-GLP-1 dual agonist compounds. United States Patent and Trademark Office. 2015.
- U.S. Food and Drug Administration. Drug Shortages Database: Tirzepatide injection. Accessed April 2026.
- Federal Food, Drug, and Cosmetic Act Section 503B. Compounding pharmacies regulations. 2013.
- Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
- Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
- Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
- Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
- Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.